Drug Database
DO

doxycycline (Perio Product / Atridox / doxycycline, Atrix)

✓ Approved

Pharmascience, Inc. · Small Molecule · Small Molecule

What is doxycycline?

doxycycline is a small molecule developed by Pharmascience, Inc.. It is approved for therapeutic indications via oral (po) or topical.

Drug Profile

Brand NamesPerio Product, Atridox, doxycycline, Atrix
CompanyPharmascience, Inc.
Drug ClassSmall Molecule
RouteOral (PO), Topical
StatusApproved
Sources: ClinicalTrials.gov, Pharmascience, Inc.

Therapeutic Indications

doxycycline is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsPeriodontitis✓ Approved

Related Research Articles

PubMedPharmacological research2026-07-25

Targeting KLF4 Degradation by Doxycycline Restores Peroxisome Lipid Metabolism and Mitochondrial Energy Production in Acute Kidney Injury.

Feng Ji J, Yao Zhi-Sheng ZS, Li Yu-Hong YH, Bai Yan Y et al.

Acute kidney injury (AKI) is a life‑threatening condition with limited preventive medications. While the transcription factor Krüppel-like factor 4 (KLF4) is critical to AKI pathophysiology, its underlying molecular mechanisms remain incompletely understood. This study investigates KLF4 from a metabolic perspective and explores the renoprotective potential of doxycycline, an FDA-approved antibiotic. In murine models of ischemia‑reperfusion (IR)‑ and cisplatin (CDDP)‑induced AKI, doxycycline administered significantly attenuated kidney injury and protected renal tubular cells from glucose deprivation- and oxygen‑glucose deprivation-induced stress in vitro. Integrative transcriptomic and metabolomic profiling revealed that AKI progression involves profound metabolic dysfunction, characterized by the downregulation of peroxisomal Acyl-CoA oxidase 3 (ACOX3) and mitochondrial Isocitrate dehydrogenase 2 (IDH2). We identified KLF4 as a dual transcriptional repressor of ACOX3 and IDH2. Mechanistically, molecular docking, surface plasmon resonance, and co-immunoprecipitation assays demonstrated that doxycycline directly binds KLF4 and promotes its ubiquitin-mediated degradation via the E3 ligase FBXO32, which restores ACOX3/IDH2-mediated fatty acid oxidation and the TCA cycle, enhancing cellular resilience against ischemic crisis. These findings define a novel KLF4‑ACOX3/IDH2 metabolic axis and highlight doxycycline as a promising repositioning candidate for AKI prevention.

PMID 42498145
Read full article →
PubMedIDCases2026-07-25

A case report of acute kidney injury due to the use of rifampicin in Brucella induced spondylodiscitis.

Bakar Lena L, Yağcı Çağlayık Dilek D

Brucellosis is the most frequently encountered zoonotic disease in regions like Turkey. Osteoarticular involvement is the most common complication, and standard treatment involves doxycycline and rifampicin. Rifampicin is generally well tolerated; however, hepatotoxicity is a known side effect, and acute kidney injury (AKI) has rarely been reported in the literature. We present a 79-year-old male with Brucella spondylodiscitis who developed progressive AKI (creatinine rising from 0.99 to 2.14 mg/dL) following 14 days of rifampicin therapy. Renal function fully recovered after rifampicin discontinuation and supportive hydration over three months. Clinicians should monitor renal function closely during rifampicin therapy and consider drug-induced AKI early, doxycycline was discontinued prior to any renal deterioration, and ciprofloxacin was continued throughout recovery, strongly implicating rifampicin as the causative agent.

PMID 42500331
Read full article →
PubMedFrontiers in microbiology2026-07-25

Advancing the diagnosis of scrub typhus with targeted next-generation sequencing.

Qin Weijuan W, Guo Yuni Y, Lei Ming M, Wei Huanhuan H et al.

Scrub typhus has nonspecific symptoms, making it easy to miss or underdiagnose. This retrospective study evaluated targeted next-generation sequencing (tNGS) for the early diagnosis of acute Orientia tsutsugamushi infection in terms of feasibility and application value. This retrospective study included 49 patients with suspected scrub typhus as the case group. Among them, 28 patients with eschar or ulcers were assigned to the clinical diagnosis group. The remaining 21 patients without eschar or ulcers formed the clinically suspected group. Additionally, 48 patients with nonscrub typhus bloodstream infections during the same period were included in the negative control group. Clinical data and tNGS results were collected for all the patients. No significant differences were found between the clinical diagnosis group and the clinically suspected group in sex, age, time from onset to sampling, season of onset, complications, or clinical prognosis (p > 0.05). The sensitivity of tNGS for diagnosing scrub typhus was 91.8% (45/49), and the specificity was 100.0% (48/48). No significant differences were observed between the clinically diagnosed group and the clinically suspected group regarding the positivity rate of O. tsutsugamushi detected by tNGS or the therapeutic response to doxycycline (p > 0.05). Significant changes were observed in the median eosinophil count (EOS), platelet count (PLT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) before and after doxycycline treatment in the case group (p < 0.001). TNGS demonstrated high sensitivity and specificity for the detection of O. tsutsugamushi. It facilitates the early diagnosis of scrub typhus, particularly in suspected cases without eschars. However, prospective studies are needed for validation.

PMID 42499666
Read full article →
PubMedBMJ case reports2026-07-25

Brucellosis-associated haemophagocytic lymphohistiocytosis in a child.

Kour Ahmad Zaher AZ, Al Abri Hamda H

Haemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that may be triggered by infections, including brucellosis. Brucellosis-associated HLH is uncommon in children and may mimic malignancy or severe viral illness.We report a school-aged boy who presented with prolonged fever, pancytopenia, hepatosplenomegaly, hyperferritinaemia, hypertriglyceridaemia and hypofibrinogenaemia, fulfilling six HLH-2004 diagnostic criteria. Blood cultures confirmed Brucella species infection.Targeted antimicrobial therapy with gentamicin, doxycycline and rifampicin resulted in complete clinical and haematological recovery without corticosteroids, intravenous immunoglobulin or cytotoxic therapy.This case highlights the importance of recognising infection-triggered HLH in endemic regions and demonstrates that early treatment of the underlying infection may reverse the hyperinflammatory state.

PMID 42498318
Read full article →
PubMedCureus2026-07-25

Severe Thrombocytopenia and Leukopenia as the Initial Manifestations of Brucella melitensis Bacteremia: A Case Report.

Pico Mendoza Carolina C, Hernandez Soto Linda E LE, Gomez Zapata Jose F JF, Vazquez Enriquez Luisa F LF et al.

Brucellosis is a zoonotic infection with diverse clinical manifestations that frequently delay diagnosis because of its nonspecific presentation. Hematologic abnormalities have been described in affected patients; however, severe thrombocytopenia remains an uncommon finding. We present the case of a 50-year-old woman who was admitted with a four-day history of fever up to 39°C, diffuse abdominal pain, vomiting, and secretory diarrhea. Initial laboratory evaluation revealed leukopenia (2.7 × 10³/μL), severe thrombocytopenia (29 × 10³/μL), hyponatremia, and elevated liver enzymes. The patient remained hemodynamically stable and showed progressive clinical improvement with supportive management. As part of the etiologic workup, two independent blood cultures yielded Brucella melitensis, establishing the diagnosis of systemic brucellosis. Further evaluation identified a history of unpasteurized milk consumption, and the 2-mercaptoethanol test was positive. Treatment with doxycycline and rifampin was initiated, and the patient subsequently demonstrated progressive clinical recovery, recovery of leukocyte and platelet counts, and improvement in biochemical abnormalities. This case highlights the importance of considering brucellosis in the differential diagnosis of patients presenting with acute febrile illness, severe thrombocytopenia, and leukopenia, even in the absence of classic focal manifestations of the disease.

PMID 42500774
Read full article →
PubMedHCA healthcare journal of medicine2026-07-25

Autoimmune Hemolytic Anemia Associated With Leptospirosis: A Rare Complication.

Waqar Anum A, Mazhar Furqan F, Afzal Mahrukh M, Razzaq Sadia S et al.

Autoimmune hemolytic anemia (AIHA) is rare but potentially life-threatening complication of leptospirosis, a zoonotic infection caused by the Leptospira species. Autoimmune hemolytic anemia occurs when the immune system targets red blood cells, resulting in hemolysis and anemia. The relationship between leptospirosis and AIHA is uncommon and often under-recognized, which can delay diagnosis and management. This case highlights the importance of considering hematologic complications in leptospirosis. A 23-year-old male presented with low-grade fever, productive cough, shortness of breath, jaundice, and pallor for 15 days. On examination, he was pale and icteric with bilateral chest crepitations. Laboratory studies showed severe anemia (hemoglobin 5.5 g/dL), elevated lactate dehydrogenase (1027 U/L), hyperbilirubinemia, thrombocytopenia, and peripheral smear evidence of hemolysis. A direct Coombs' test was strongly positive. Leptospira immunoglobulin M serology confirmed the diagnosis. The patient was managed with broad-spectrum antibiotics (piperacillin-tazobactam and doxycycline) and high-dose corticosteroids (1 mg/kg/day). He improved clinically with stabilization of hemoglobin and a resolution of symptoms. This case demonstrates a rare immune-mediated manifestation of leptospirosis presenting as AIHA without hepatic or renal failure. Clinicians should maintain a high index of suspicion for hematologic complications in leptospirosis. Early recognition and timely initiation of corticosteroid therapy alongside antibiotics can improve patient outcomes.

PMID 42500446
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about doxycycline